Jan 21 (Reuters) - Lepu Biopharma Co Ltd 2157.HK:
ENTERS EXCLUSIVE LICENSE WITH LEPU BIOPHARMA FOR MRG007, AN ANTIBODY DRUG CONJUGATE FOR THE TREATMENT OF GASTROINTESTINAL CANCERS
Source text: ID:nGNX8rlqWM
Further company coverage: 2157.HK
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.